Baldessarini Ross J, Tondo Leonardo, Davis Paula, Pompili Maurizio, Goodwin Frederick K, Hennen John
International Consortium for Research on Bipolar Disorders, Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA, USA.
Bipolar Disord. 2006 Oct;8(5 Pt 2):625-39. doi: 10.1111/j.1399-5618.2006.00344.x.
To update and extend comparisons of rates of suicides and suicide attempts among patients with major affective disorders with versus without long-term lithium treatment.
Broad searching yielded 45 studies providing rates of suicidal acts during lithium treatment, including 34 also providing rates without lithium treatment. We scored study quality, tested between-study variance, and examined suicidal rates on versus off lithium by meta-analytic methods to determine risk ratios (RRs) and 95% confidence intervals (CI).
In 31 studies suitable for meta-analysis, involving a total of 85,229 person-years of risk-exposure, the overall risk of suicides and attempts was five times less among lithium-treated subjects than among those not treated with lithium (RR = 4.91, 95% CI 3.82-6.31, p < 0.0001). Similar effects were found with other meta-analytic methods, as well as for completed versus attempted suicide, and for bipolar versus major mood disorder patients. Studies with higher quality ratings, including randomized, controlled trials, involved shorter exposures with somewhat lesser lithium superiority. Omitting one very large study or those involving lithium-discontinuation had little effect on the results. The incidence-ratio of attempts-to-suicides increased 2.5 times with lithium-treatment, indicating reduced lethality of suicidal acts. There was no indication of bias toward reporting positive findings, nor were outcomes significantly influenced by publication-year or study size.
Risks of completed and attempted suicide were consistently lower, by approximately 80%, during treatment of bipolar and other major affective disorder patients with lithium for an average of 18 months. These benefits were sustained in randomized as well as open clinical trials.
更新并扩展对接受与未接受长期锂盐治疗的重度情感障碍患者自杀率及自杀未遂率的比较。
广泛检索得到45项提供锂盐治疗期间自杀行为发生率的研究,其中34项还提供了未使用锂盐治疗时的发生率。我们对研究质量进行评分,检验研究间的异质性,并通过荟萃分析方法检查锂盐治疗与未治疗时的自杀率,以确定风险比(RRs)和95%置信区间(CI)。
在31项适合进行荟萃分析的研究中,总计有85229人年的风险暴露时间,接受锂盐治疗的受试者自杀和自杀未遂的总体风险比未接受锂盐治疗的受试者低五倍(RR = 4.91,95% CI 3.82 - 6.31,p < 0.0001)。其他荟萃分析方法也得到了类似结果,对于自杀既遂与自杀未遂、双相情感障碍患者与重度心境障碍患者均如此。质量评分较高的研究,包括随机对照试验,暴露时间较短,锂盐的优势也稍小。剔除一项非常大型的研究或那些涉及停用锂盐的研究对结果影响不大。锂盐治疗使自杀未遂与自杀既遂的发生率之比增加了2.5倍,表明自杀行为的致死性降低。没有迹象表明存在偏向报告阳性结果的偏倚,结果也未受到发表年份或研究规模的显著影响。
在双相情感障碍和其他重度情感障碍患者中,平均接受18个月锂盐治疗期间,自杀既遂和自杀未遂的风险持续降低约80%。这些益处在随机临床试验和开放临床试验中均得到维持。